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A therosclerosis is a chronic inflammatory response to injury in the vessel wall, yet the initiating events that precede leukocyte accumulation and fat deposition leading to plaque development remain poorly defined. Mineralocorticoid receptor (MR) antagonists, administered as diuretics at doses that do not significantly lower blood pressure, improve survival in heart failure (1), and acute myocardial infarction (2) in humans. Activation of MR in the vasculature is also proinflammatory and proatherogenic (3), suggesting protective effects of MR antagonism on the cardiovascular system, independent of blood pressure. However, the mechanisms associated with these cardio-protective effects in humans are yet to be determined. MR are also high affinity glucocorticoid receptors (4) , yet in mineralocorticoid target tissues, including the distal nephron, MR are selective for aldosterone, their physiological ligand, despite higher (ϳ100-fold) circulating levels of glucocorticoid (5) . This selectivity at least in part is a consequence of prereceptor metabolism of glucocorticoids to intrinsically inert 11-keto-glucocorticoids by 11␤-hydroxysteroid dehydrogenase type 2 (11␤-HSD2) (6) . The pathophysiologic importance of 11␤-HSD2 is demonstrated in patients with the syndrome of apparent mineralocorticoid excess caused by mutations in Hsd11b2, the human gene encoding 11␤-HSD2 (7) . Loss of 11␤-HSD2 results in inappropriate activation of MR by glucocorticoids in the distal nephron causing hypokalemia and hypertension (8) . Similarly, 11␤-HSD2 Ϫ/Ϫ mice are also hypertensive, with activation of MR in the distal nephron causing increased sodium reabsorption and potassium excretion (9) . Evidence supports a proatherogenic action of cortisol within the vessel wall (10) . Glucocorticoid pharmacotherapy in humans is associated with increased cardiovascular events (11) .
We and others have demonstrated the existence of the MR/11␤-HSD2 system in nonepithelial tissues, including the vasculature (12) . Thus, proatherogenic effects of MR activation could be mediated directly by increased mineralocorticoid hormones or through by-pass or reduced activity of vascular 11␤-HSD2, permitting glucocorticoid activation of vascular MR. All known inhibitors of 11␤-HSD2 can also inhibit 11␤-HSD1 activity (13) and compromise the endothelial barrier by interacting with tight junction proteins (14) . Therefore, we have investigated the underlying mechanism in Apoe Ϫ/Ϫ /Hsd11b2 Ϫ/Ϫ doubleknockout (E/b2) mice, lacking both apolipoprotein E (ApoE) and 11␤-HSD2.
Materials and Methods

Generation of ApoE/Hsd11b2 double-knockout animals
All animal studies were conducted in accordance with the National Institutes of Health guidelines for the Care and Use of Laboratory Animals under the auspices of the Animals (Scientific Procedures) Act UK 1986 after prior approval by the local ethical committee. The previously targeted Hsd11b2 allele (9) was transferred to C57BL/6J by nine generations of consecutive backcrosses. Two C57Bl/6J females homozygous for deletion of the Hsd11b2 allele were crossed with an Apoe-knockout (Apoe Ϫ/Ϫ ) male on the C57Bl/6J background (Charles River, L'Arbresle Cedex, France) derived from the original knockout line (15) . Double heterozygous male offspring (Apoe 
/Hsd11b2
Ϫ/Ϫ knockout males (E/b2) to Apoe Ϫ/Ϫ
ϩ/Ϫ females; double-knockout E/b2 progeny was selected for experimental protocols. Genotyping was performed by PCR using genomic DNA extracted from ear clips. Apoe primers were located outside the neocassette inserted into exons 3 and 4 (ApoEex3f, AAC TTA CTC TAC ACA GGA TGC C; Apoe ex4r, CGT CAT AGT GTC CTC CAT CAG TGC). These primers amplify both the wild-type allele (584 bp) and the knockout allele (1500 bp). PCR conditions were as follows: denaturation at 94 C for 5 min, then 3 min of elongation at 72 C, followed by 32 cycles of 94 C for 30 sec, 58 C for 1 min, and 72 C for 2 min. The Hsd11b2 allele (981 bp) was amplified with primers 11b2_679f, AGG CTG ATG ATA GAT TCA CGA GAC; and 11b2_1660r, CGA ATG TGT CCA TAA GCA GTG. The knockout allele was amplified using the genomic primer 11b2_679f (above) and primer Neof1441, GCG AAT GGG CTG ACC GCT TCC TCG, complementary to the Neo gene sequence in the targeting cassette inserted in the reverse orientation.
Animal treatments
Male Apoe Ϫ/Ϫ and E/b2 mice were maintained on normal chow diet with water ad libitum and a 12-h light, 12-h dark cycle. Systolic blood pressure (SBP) was measured in conscious, restrained mice by noninvasive tail cuff plethysmography (16) . This procedure was repeated on a weekly basis during the first month followed by monthly measurements until termination. Representative Apoe Ϫ/Ϫ and E/b2 mice were killed by asphyxiation with CO 2 at age 3 and 6 months for assessment of atherosclerotic lesion formation. To evaluate the effects of drugs, 2-month-old male E/b2 and Apoe Ϫ/Ϫ mice were randomized to receive normal chow diet containing the MR antagonist eplerenone (200 mg/kg ⅐ d), the epithelial sodium channel (ENaC) blocker amiloride (1 mg/kg ⅐ d; n ϭ 9) that acts downstream of renal MR to lower blood pressure (17) , or vehicle for 3 months.
Tissue preparation for assessment of atherosclerosis
After euthanasia, the vasculature was perfusion fixed in situ with 10% neutral-buffered paraformaldehyde via the left ventricle. Arteries removed included the aorta and the following major branches: brachiocephalic (innominate) artery and its branches, the right subclavian and right common carotid arteries, the left common carotid and left subclavian arteries, and the major branches of the abdominal aorta, including the celiac, superior mesenteric arteries, and the renal arteries.
Semiquantitative gross assessment of atherosclerosis in the arterial tree
Adventitia were dissected from fixed arteries under a dissecting microscope. Atherosclerotic lesions were visualized through the translucent arterial wall as yellowish-white opaque deposits. A semiquantitative scoring system was applied for atherosclerotic deposits at the following sites: 1) lesser curvature of the aortic arch, 2) origins of principal branches of thoracic aorta (brachiocephalic, left common carotid, and left subclavian arteries), 3) origin of right and distal right and left common carotid arteries, 4) distal right and left subclavian arteries, and 5) principal branches of abdominal aorta (celiac, superior mesenteric, and renal arteries). Scoring was based on the following criteria: 0, absent; 1, trace; 2, mild; 3, moderate; and 4, severe.
Arterial trees from all mice of both genotypes were coded and read blind by two independent observers. For each site, the arterial tree with the most severe deposit was assigned a score of 4. The remaining coded arterial trees were then assigned a score based on that sample.
Quantification of atherosclerotic lesion size
The brachiocephalic artery was dissected out to provide a Y-shaped piece of vessel containing the origins of the subclavian and carotid arteries; this was embedded in paraffin. Serial sections (3 m) were taken from the proximal 60 m of the brachiocephalic artery once the leaflets of the aortic arch were no longer visible. Sections were stained with US trichrome (UST); plaque sizes were quantified by light microscopy (Zeiss Axioscop; magnification, ϫ10; Zeiss, Oberkochen, Germany) with computerized planimetry (MCID Basic 7.0 image analysis software; Imaging Research, Inc., Brock University, St. Catherines, Ontario, Canada). The area inside the internal elastic lamina was subtracted from the area inside the external elastic lamina to provide a measure of media area. Subclavian arteries from randomly selected mice in the drug study were also paraffin embedded and sectioned as above for morphometric studies.
Immunohistochemistry
Plaque collagen content was assessed by Picrosirius red staining and extracellular lipid content by quantification of the holes left behind during histological processing of UST-stained sections (18) . Plaque macrophage and smooth muscle cell (SMC) content was assessed using Mac-2 (VH BIO, Gateshead, UK) and smooth muscle ␣-actin (Sigma, Poole, UK) antibodies, respectively. Vascular cell adhesion molecule 1 (VCAM-1) (Cambridge Biosciences, Cambridge, UK) antibody was used to investigate adhesion molecule expression (for details, please see Supplemental data, published on The Endocrine Society's Journals Online web site at http://endo.endojournals.org). Staining was imaged using a light microscope (Zeiss Axioskop) coupled to a Photometrics CoolSnap camera (Tucson, AZ). Photoshop CS3 Extended software was used to quantify staining, and data are expressed as stained areas relative to total plaque size (percentage). A semiquantitative scoring method (carried out blind to genotype) was employed to assess VCAM-1 expression, where an arbitrary score of 0 -4 was given to each section based on the percentage of the circumference of the specific endothelial staining.
Cell culture
Mouse aortic endothelial cells (MAECs cell line) (19) were maintained in endothelial basal medium 2 (Lonza, Slough, UK) supplemented with 10% fetal calf serum and Pen/Strep. Cells were treated overnight in serum-free medium with one of the following: 10 ng/ml TNF-␣ (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), 1 nM aldosterone in the presence/absence of 1 M spironolactone, 1 nM corticosterone in the presence/absence of 1 M glycyrrhetinic acid, and 1 M spironalactone (all from Sigma). VCAM-1 expression was quantified by counting the number of positively stained cells per field (at magnification, ϫ40) in four separate fields for each treatment.
FIG. 1. Accelerated atherosclerosis in Apoe
Ϫ/Ϫ mice on a standard low-fat diet. A, Atherosclerotic lesions and outward remodeling were evident in the brachiocephalic arteries of 3-month-old E/b2 mice but not in Apoe Ϫ/Ϫ mice (UST stain; magnification, ϫ10). B, At 6 months of age, lesion development and outward remodeling were significantly greater in E/b2 than in Apoe Ϫ/Ϫ mice. The example used for Apoe
shows the largest plaque seen at this age (UST stain; magnification, ϫ10). Lesions in E/b2 were more complex with evidence of buried fibrous caps (black arrows). Scale bar, 250 m. C, Quantitative analysis confirmed that lesion sizes were increased, and lumens were reduced in E/b2 mice compared with Apoe Ϫ/Ϫ mice. Data are means Ϯ SEM; *, P Ͻ 0.05; **, P Ͻ 0.01 compared with Apoe Ϫ/Ϫ using Student's unpaired t test (n ϭ 4 -8). Histological analysis of brachiocephalic arteries identified extensive atherosclerotic lesions in 3-month-old E/b2 mice but not in age-matched Apoe Ϫ/Ϫ mice. At 6 months of age, lesion size remained significantly increased in E/b2 compared with Apoe Ϫ/Ϫ mice. The differences in lesion size were significant whether expressed as mm 2 or as a percentage of the lesion area (lesion/area inside the external elastic lamina ϫ 100) ( Fig. 1 ). Increased lesion development in E/b2 mice reduced the percentage luminal area (lumen/lumen ϩ lesion area ϫ 100), compared with Apoe Ϫ/Ϫ mice mice at both 3 and 6 months of age ( Fig. 1) . Absolute lumen area (mm 2 ) was not reduced in E/b2 mice due to extensive outward remodeling of the vessel (indicated by increased total area within the external elastic lamina). Buried fibrous caps were evident only in 6-month-old E/b2 mice. These may be an indication of lesion 'vulnerability.' Data are mean ϩ SEM, with group sizes shown in parentheses (n). EEL, External elastic lamina. a P Ͻ 0.05. b P Ͻ 0.01 compared to age-matched Apoe Ϫ/Ϫ mice (Student's unpaired t test).
Plasma lipid and lipoprotein analysis
Terminal blood samples were taken for lipid analysis from the left ventricle of vehicle-and drug-treated E/b2 and Apoe Ϫ/Ϫ mice. Total plasma cholesterol was measured by a colorimetric reaction using the Cholesterol/Cholesteryl Ester Quantification kit (Merck, Whitehouse Station, NJ).
Statistical analyses
Data were analyzed by the GraphPad Prism analysis package (GraphPad, San Diego, CA). Data are expressed as means Ϯ SEM. For analysis of unpaired datasets, Student's unpaired t test was used for comparison of two groups, and one-way ANOVA with Tukey's post hoc test was used for more than two groups. Repeated measures ANOVA was used for comparison of matched datasets. Two-way ANOVA followed by Bonferroni post hoc tests was used for analyzing the effects of drug treatments between groups. Scored data were analyzed by a nonparametric Kruskal-Wallis oneway ANOVA followed by Dunn's post hoc test. A P value of less than 0.05 was considered to be statistically significant. 1A) . In contrast, by 3 months of age on the same diet, E/b2 mice lacking both 11␤-HSD2 and ApoE displayed atheroma (lipid core and proliferating SMCs) with occasional thin fibrous caps, affecting the aortic arch and its major branches, including the brachiocephalic trunk (Fig. 1A) , a site particularly susceptible to plaque development in these animals when fed an atherogenic "Western" diet (20) . At 3 months, some severe lesions were already present in E/b2 mice, with extended necrotic areas, cholesterol clefts, neointimal expansion, and elastic lamina remodeling. By 6 months of age, E/b2 mice displayed complex severe atherosclerotic FIG. 2. Accelerated atherosclerosis in E/b2 mice is associated with macrophage infiltration and altered plaque composition. A, At 3 months of age, Apoe Ϫ/Ϫ mice are lesion free, whereas E/b2 mice show macrophage-infiltrated plaques (staining with anti-Mac-2 antibodies) with a high lipid and low collagen content. By 6 months, E/b2 mice have large macrophagerich plaques with a high density of lipids and sparse collagen staining. In comparison, 6-month-old Apoe Ϫ/Ϫ mice have plaques that are rich in collagen and low in lipid and macrophage content. E/b2 and Apoe Ϫ/Ϫ mice at both ages show similar levels of ␣-SMA staining, indicative of SMC within their plaques. Representative images (of six mice per group, except in case of 6-month-old Apoe Ϫ/Ϫ , where uncommon larger plaques were selected to investigate composition) captured at magnification, ϫ10. Arrows indicate regions of interest corresponding to names of each column. Scale bar, 250 m. B-E, The area of staining for each plaque component was quantified using Photoshop CS3 Extended software and expressed as a percentage of total plaque area. Macrophage (B) and lipid (C) contents were both increased in brachiocephalic plaques from 3-and 6-month-old E/b2 mice compared with those from Apoe Ϫ/Ϫ mice at 6 months of age. There was no difference in the ␣-SMA (D) content of plaques between Apoe Ϫ/Ϫ and E/b2 mice at either 3 or 6 months of age. Collagen (E) content was reduced in brachiocephalic plaques from 3-and 6-month E/b2 mice compared with those from Apoe Ϫ/Ϫ mice at 6 months of age. Data are mean Ϯ SEM, n ϭ 5-7/group. Analyzed by two-way ANOVA; *, P Ͻ 0.05; **, P Ͻ 0.005.
Results
lesions with multiple fibrous caps (Fig. 1B) . Importantly, these included buried caps, which have been suggested as being indicative of earlier plaque instability (Fig. 1B and Table 1 ) (21) . However, in 6-month-old Apoe Ϫ/Ϫ mice raised on the same chow diet, atherosclerosis remained sporadic (only one of the six animals in this group had a notable plaque; example shown in Fig. 1B ) in the brachiocephalic artery (Fig. 1B) . This remarkable increase in atherosclerosis with 11␤-HSD2 deficiency was despite similar plasma cholesterol levels between E/b2 (306 Ϯ 54 mg/dl) and Apoe Ϫ/Ϫ (288 Ϯ 46 mg/dl) mice. Quantitative analysis of the areas inside the external elastic lamina, lesion areas, and lumen areas of the brachiocephalic artery revealed significantly larger atherosclerotic lesions in E/b2 mice at 3 and 6 months of age compared with age-matched Apoe Ϫ/Ϫ mice ( Fig. 1C and Table 1 ). There was also a significant reduction of lumen size relative to the size of the vessel (Fig. 1C and Table 1 ), although the absolute lumen size was maintained (vessel diameter was also increased), suggestive of expansive remodeling in E/b2 mice.
Plaque composition is altered in E/b2 mice
Immunohistochemical staining revealed that atherosclerotic plaques in brachiocephalic arteries of 6-month-old E/b2 mice contained dense accumulations of macrophages and foam cells ( Fig. 2A) , most notably at the "shoulder" of lesions and near buried fibrous caps. Macrophage infiltration (Fig. 2B) , and lipid content of plaques (Fig. 2C) were both significantly greater in E/b2 than in Apoe Ϫ/Ϫ mice. Furthermore, plaques in 3-month-old Eb/2 mice contained significantly more macrophages (Fig. 2B) and lipid ( Fig. 2C ) than those in plaque size-matched Apoe Ϫ/Ϫ counterparts (examples of rare plaques from 6-month-old Apoe Ϫ/Ϫ mice selected to show composition). SMC content of plaques, assessed by ␣-smooth muscle actin (SMA) immunoreactivity, did not differ between E/b2 and Apoe Ϫ/Ϫ mice (Fig. 2D) . Picrosirius red staining of collagen was significantly lower in plaques from 3-and 6-month-old E/b2 mice compared with plaques from 6-month-old Apoe Ϫ/Ϫ mice (Fig. 2E) . Thus, 11␤-HSD2 deficiency promotes the formation of collagen-poor, lipid-, and macrophage-rich plaques, suggestive of a "vulnerable" plaque phenotype.
Accelerated atherosclerosis in E/b2 mice is associated with increased expression of VCAM-1 VCAM-1 immunoreactivity was significantly higher in unaffected areas of brachiocephalic artery endothelium in both 3-and 6-month-old E/b2 mice compared with agematched Apoe Ϫ/Ϫ controls ( Fig. 3 ) both in the endothelium covering the plaque and in plaque-free regions of the vessel wall. Importantly, comparison of similar-sized vessels from 3-month-old E/b2 mice and 6-month-old Apoe Ϫ/Ϫ mice showed significantly higher VCAM-1 expression in E/b2 mice, despite their younger age (Fig. 3, A and B). boxes) . Adventitia is stained nonspecifically as a result of entrapment of streptavidin-horseradish peroxidase complex (see negative control). Representative images (of four to six mice per group) captured at magnification, ϫ10. Scale bar, 250 m. B, VCAM-1 staining is significantly greater in endothelium of 3-and 6-month-old E/b2 mice compared with age-matched Apoe Ϫ/Ϫ mice. At 3 months, VCAM-1 expression is higher in E/b2 vessels compared with Apoe Ϫ/Ϫ mice at 6 months with the same size of plaques. Data are means Ϯ SEM, n ϭ 4 -6/group. Analyzed by Kruskal-Wallis nonparametric test; ***, P Ͻ 0.0001. Scoring: 0, absent; 1, Ͻ25% circumference stained; 2, 25-50% circumference stained; 3, 50 -75% circumference stained; 4, Ͼ75% circumference stained.
sclerosis in E/b2 mice could be attributable to hypertension as a result of renal MR activation by glucocorticoids, or to a direct effect of 11␤-HSD2-deficiency within the vascular wall or a combination of these factors. To address MR involvement and to determine the dependency of the phenotype on hypertension, 2-month-old mice were fed chow diet containing vehicle or one of two pharmacologic inhibitors for 3 months: amiloride, an ENaC blocker that acts downstream of renal MR to lower blood pressure, and eplerenone, a highly selective MR antagonist. The dose chosen for the latter (200 mg/kg ⅐ d in chow) was previously shown to reduce atheroma formation in Apoe Ϫ/Ϫ mice administered aldosterone (22) . We found no effect of any drug treatment on blood pressure of Apoe Ϫ/Ϫ mice (data not shown).
Eplerenone had no significant effect on SBP in E/b2 mice, whereas amiloride reduced it by approximately 11 mm Hg, almost halving the blood pressure difference between E/b2 and Apoe Ϫ/Ϫ mice (Fig. 4A) . However, despite being less effective as a hypotensive drug, eplerenone was more effective than amiloride in reducing overall plaque score as estimated by blinded, semiquantitative scoring assessed across five sites (Fig. 4 , B and C). Quantitative histological analysis showed that eplerenone also dramatically reduced plaque size and the expansive remodeling in subclavian arteries, which are particularly prone to large occlusive plaques in E/b2 mice (Fig. 4, D and E) . Both eplerenone and amiloride reduced lesion size in brachiocephalic arteries (Fig. 4 , F and G, and Table 2 ). The pattern of expansive remodeling evident in untreated E/b2 mice was also reduced after treatment with both eplerenone and amiloride (Table 2) . Thus, the stronger atheroprotective effect of eplerenone in comparison with amiloride, with the latter producing a larger reduction in blood pressure, indicates that the predominant mechanism leading to accelerated atherosclerosis in E/b2 mice is unlikely to be attributable simply to hypertension after renal MR activation.
MR activation contributes to the altered plaque composition in E/b2 mice
To investigate whether MR antagonism altered plaque composition in addition to reducing lesion size in E/b2 mice, macrophage infiltration, ␣-SMA, collagen, and lipid content were measured in brachiocephalic plaques of E/ b2   FIG. 4 . Eplerenone reduces lesion size in E/b2 mice, independently of blood pressure. A, SBP in E/b2 and Apoe Ϫ/Ϫ mice was reduced in E/b2 mice by treatment with amiloride but not by eplerenone. *, P Ͻ 0.05 vs. age 3 and 4 months, repeated measures ANOVA. B, Representative images of the aortic arch and its branches in 5-month-old E/b2 mice after vehicle (left panel), amiloride (center panel), or eplerenone (right panel) treatment. aa, Aortic arch; ca, carotid artery; sca, subclavian artery; bc, brachiocephalic artery. C, Semiquantitative analysis of lesion development using global plaque score (for details, please see Materials and Methods). **, P Ͻ 0.01 vs. untreated E/b2 Kruskal-Wallis test, n ϭ 6 -11. D, Representative images of UST-stained plaques in subclavian arteries of 5-month-old E/b2 mice after vehicle (left), amiloride (center), and eplerenone (right) treatment. Images captured at magnification, ϫ10. Scale bar, 250 m. E, Measurement of lesion size; *, P Ͻ 0.05 vs. untreated E/b2 mice, one-way ANOVA, n ϭ 4 -5). F, Representative images of UST-stained plaques in brachiocephalic arteries of E/b2 mice after vehicle (left), amiloride (center), and eplerenone (right) treatment. Images captured at magnification, ϫ10. Scale bar, 250 m. G, Measurement of lesion size; *, P Ͻ 0.05 vs. untreated E/b2; two-way ANOVA, n ϭ 7-10.
Endocrinology, January 2011, 152(1):236 -246 endo.endojournals.orgmice after 3 months of treatment with eplerenone or vehicle. Macrophage content was significantly reduced by eplerenone treatment (Fig. 5, A and B) . Despite the increase in lipid content of plaques in E/b2 mice compared with Apoe Ϫ/Ϫ mice, MR blockade with eplerenone had no effect on plaque lipid content in E/b2 mice (Fig. 5, A and  C) . Surprisingly, although there was no difference in plaque ␣-SMA content between E/b2 and Apoe Ϫ/Ϫ mice, SMC content was significantly increased by MR blockade in E/b2 mice (Fig. 5, A and D) . Eplerenone treatment also significantly increased plaque collagen content compared with vehicle-treated E/2b mice (Fig. 5, A and E ). There was a trend toward a reduction in the incidence of buried fibrous caps in the brachiocephalic artery of eplerenonetreated E/b2 mice (1.10 Ϯ 0.31 buried caps for vehicletreated mice vs. 0.56 Ϯ 0.18 for eplerenone-treated E/b2 mice).
Glucocorticoids in the presence of 11␤-HSD2 inhibitor cause MR-mediated up-regulation of VCAM-1 expression in vitro
MAECs were used to test whether mineralocorticoids or glucocorticoids acting through MR can affect VCAM-1 expression and whether 11␤-HSD2 inhibition may be important in regulation of MR specificity. Similar to TNF-␣, which potently increases VCAM-1 expression in endothelial cells (23) , aldosterone markedly increased the number of MAEC expressing VCAM-1 (Ͼ7-fold) (Fig. 6) , an effect blocked by pretreatment with the MR antagonist, spironolactone, suggesting an MR-mediated mechanism. Corticosterone alone had no effect on VCAM-1 expression. However, inhibition of 11␤-HSD2 by pretreatment with glycyrrhetinic acid [a widely used 11␤-HSD inhibitor (24) , which had no effect on VCAM-1 expression on its own] allowed corticosterone to induce a more than 9-fold increase in the number of VCAM-1-stained cells (Fig. 6) . Using RT-PCR, we have confirmed that 11␤-HSD1 is not expressed in MAEC (data not shown). Thus, in this cell line, as in kidney, 11␤-HSD2 protects MR from activation by glucocorticoids. Consistent with MR involvement, VCAM-1 up-regulation by corticosterone in the presence of glycyrrhetinic acid was reversed by blockade of MR with spironolactone (Fig. 6B) .
Discussion
Early development of severe occlusive atheromatous plaques in E/b2 mice provides a new experimental model of atherosclerosis, mechanistically underpinned by glucocorticoid-mediated activation of MR. In contrast to most existing models, high fat/Western diet is not required for the development of atherosclerosis in Eb/2 mice. Indeed, when fed a chow diet, Apoe Ϫ/Ϫ mice exhibit moderate hyperlipidemia and only develop mature atheromatous plaques at 8 -10 months of age (25) . Feeding Apoe Ϫ/Ϫ mice a Western diet (containing cholesterol) increases plasma cholesterol, induces systemic inflammation, and accelerates atherogenesis so that lesions appear within 5 wk (20) . It therefore appears that progressive atherosclerosis in Apoe Ϫ/Ϫ mice is strictly dependent on systemic inflammation and elevated plasma cholesterol associated with the Western diet.
Atherogenesis in E/b2 mice was associated with early and increased macrophage infiltration of brachiocephalic lesions, even when matched with similar-sized lesions in older Apoe Ϫ/Ϫ mice. An increase in the number of buried caps in plaques of older E/b2 animals could reflect multiple events of plaque rupture and repair in E/b2 mice, typical of vulnerable plaques. Thus, for investigation of the processes leading to a vulnerable plaque phenotype, E/b2 mice may be a better experimental platform than Apoe Ϫ/Ϫ mice.
The ability of eplerenone administration to reduce plaque size and alter plaque composition implicates MR activation as mechanistically important in accelerating atherosclerosis in E/b2 mice. This is consistent with previous data showing that aldosterone is proatherogenic in animal models (23, 26) , although this has not been replicated in all studies (27) . Moreover, eplerenone has beneficial effects on experimental atherosclerosis in nonhuman primates (28) , again implicating MR activation in pathogenesis of atherosclerosis. This raises the possibility that the proatherogenic effects of MR activation are through cortisol (a glucocorticoid) rather than the mineralocorticoid, aldosterone.
Crucially, the effect of eplerenone on atherosclerosis in E/b2 mice was independent of MR effects on blood pressure (which was unaltered in E/b2 mice by this modest dose of eplerenone). In the absence of 11␤-HSD2, MR are not protected from activation by glucocorticoids, and their activation in the distal nephron increases activity of ENaCs and Na/K ATPase, leading to hypertension (17) . The extent of hypertension in E/b2 mice was comparable with that previously reported in single-knockout Hsd11b2 Ϫ/Ϫ mice (9).
Bypassing MR activation with the ENaC blocker amiloride reduced blood pressure in E/b2 mice but was less effective in diminishing atherosclerosis than eplerenone. Hypertension in Hsd11b2 Ϫ/Ϫ mice is initiated by MR activation and volume expansion, but already after 2.5 months of age, activity of ENaC was returned to the basal level, and high blood pressure was maintained by activation of ␣ 1-adrenergic receptors (26) . Hence, eplerenone cannot effectively normalize blood pressure at these later stages, whereas amiloride still can. Another possible contributor to hypertension in Hsd11b2 deficiency is the vasoconstrictive effect mediated by glucocorticoid receptors (29, 30), which will not be affected by the MR antagonist, eplerenone. Thus, although hypertension may play a part in the accelerated atherogenesis in E/b2 mice, there is clearly a component of atherogenesis that is not merely due to the hypertension of "apparent mineralocorticoid excess" produced by MR overactivation in the distal nephron. This concurs with two previous studies in which blood pressure played little or no role in atherogenesis: in mice deficient for both ApoE and endothelial nitric oxide synthase (31) and Apoe Ϫ/Ϫ mice with renovascular hypertension (one kidney/one clip and two kidneys/two clips models) (32) . In contrast, blood pressure per se played only a minor role in atheroma progression in Apoe Ϫ/Ϫ mice with renovascular hypertension compared with the large effect of angiotensin II (33) . Our data implicate activation of nonrenal MR in the pathogenesis of accelerated atherogenesis in E/b2 mice with the vascular wall being the most likely candidate site. In humans, 11␤-HSD2 immunoreactivity has been re- ported in arterioles and veins (34) with immunoreactivity and enzyme activity concentrated in endothelial cells (35) . Both 11␤-HSD2 mRNA and enzyme activity are found in rodent vessels, most likely including the endothelium (36) . Consistent with colocalization of MR and 11␤-HSD2 in endothelial cells, MAEC in vitro also have functional MR and 11␤-HSD2. In vitro, activation of MR by aldosterone increases leukocyte adhesion molecules in primary human endothelial cells from umbilical cord (37) . It was shown recently that aldosterone stimulates transcription of the proatherogenic leukocyte-endothelial cell adhesion proteins in human coronary artery and aortic endothelial cells. In the same study, inhibition of 11␤-HSD2 enhanced cortisol-induced transcription of a reporter transgene mediated by MR in aortic endothelial cells (38) . We show that VCAM-1 expression was increased in vivo in E/b2 mice in affected and unaffected regions of the brachiocephalic artery. A direct effect of MR in this increase (rather than an effect of shear stress) is supported by the MR-dependent potent increase in VCAM-1 expression in MAECs treated with aldosterone or with corticosterone in the presence of an 11␤-HSD2 inhibitor. VCAM-1 increases monocyte/macrophage adhesion to endothelial cells (39) and is mechanistically linked to inflammatory processes (40) and atheroma development in Apoe Ϫ/Ϫ (41) and Ldlr Ϫ/Ϫ mice (42) . Increased expression of VCAM-1 in E/b2 mice may be responsible for the increased macrophage infiltration leading to accelerated atherogenesis and may also stimulate expansive vessel remodeling (43) . Overall, these findings indicate that loss of function of 11␤-HSD2 leads to striking atherogenesis in E/b2 mice mediated by activation of nonrenal MR. Endothelial expression of VCAM-1 and massive infiltration of the atherosclerotic plaques by macrophages at moderately elevated levels of plasma cholesterol are the characteristic features of this new mouse model of atherosclerosis.
We have shown for the first time that 11␤-HSD2 is atheroprotective. In its absence, activation of MR mainly by glucocorticoids enhances inflammatory processes in the atherosclerotic plaque. This effect of MR is not solely attributable to changes in blood pressure. Whether it is associated with the altered activation mechanisms of MR in the endothelium remains to be investigated in the future experiments with tissue specific knockout of MR. 
